Atlas Trials

Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C Mutation

Clinical trial NCT05162443 · APPROVED_FOR_MARKETING

Trial details

NCT number
NCT05162443
Sponsor
Bristol-Myers Squibb
Status
APPROVED_FOR_MARKETING
Study type
EXPANDED_ACCESS
Advanced CancerMetastatic CancerMalignant Neoplasm

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.